Cotinga Pharmaceuticals Inc COTQF

Healthcare Biotechnology

Cotinga Pharmaceuticals Inc is a clinical-stage biopharmaceutical company. The company's lead clinical candidate, COTI-2, is an oral small molecule targeting p53, a tumor suppressor gene that is mutated in over 50% of all cancers, and the company's second clinical candidate, COTI-219, is a novel oral small molecule compound targeting the mutant forms of KRAS with such mutations occurring in up to 30% of all cancers.

GREY:COTQF - Post by User

Cotinga Pharmaceuticals Inc

Bullboard Posts

Post by kingrich9on Oct 04, 2016 7:13pm

146 Views

Post# 25309282

Agreed

The science will be the end game, so far so good. Investors should look for negative news these days, if nothing is forecoming, we are on the path to incredible success for patients and shareholders. So far.... no bad news.

Bullboard Posts

Canadian government to fund Electric Royalties portfolio property